Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Primary completion
- May 2027
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in Vitiligo comparing LY4005130 with Placebo (2 arms). Primary endpoint: Percentage of Participants Achieving Facial Vitiligo Area Scoring Index 75 at 24 weeks. Started Apr 2026; status: recruiting.
02
Drugs
LY4005130
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT07533019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07533019.